Status:
COMPLETED
Immune Profiles in CF Fungal Infection
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
University of Colorado, Denver
Conditions:
Cystic Fibrosis
Fungal Infection
Eligibility:
All Genders
8-25 years
Brief Summary
This study is investigating the role of allergic (Th2) inflammation in patients with Cystic Fibrosis (CF) and history of fungal infection and/or Allergic Bronchopulmonary Aspergillosis. Little is know...
Detailed Description
While bacteria are predominant agents in CF lung disease, fungi are often isolated in both sputum and bronchoalveolar lavage fluid (BAL), yet their role in CF is not fully understood. Fungal infection...
Eligibility Criteria
Inclusion
- Diagnosis of CF per CFF guidelines and followed at Children's Hospital Colorado (CHCO) CF Center
- Meets criteria of only one fungal group (described below)
- Clinical stability without any change acute antibiotic regimen in the past 14 days
- Clinical stability without any use for acute NSAID or oral steroids in past 14 days
- Individuals with other co-morbid conditions related to and unrelated to CF, including but not limited to CF related diabetes, CF related liver disease, asthma, etc.
Exclusion
- History of Burkholderia sp. or Non-tuberculosis Mycobacterium
- Comorbid or health contraindication to induced sputum treatment or blood draw
Key Trial Info
Start Date :
February 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04476758
Start Date
February 10 2021
End Date
October 30 2023
Last Update
July 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Hospital Colorado
Highlands Ranch, Colorado, United States, 80310